HOME >> BIOLOGY >> NEWS
Evolving slower gets you the bigger piece of the pie

A well known effect in the arms race that ensues between host and parasite, the red queen effect, states that the species that is able to evolve countermeasures faster than its partner will gain the upper hand. New research claims that this is not so when considering mutualistic interactions between species. When deciding who will gain most from the interaction, it pays to move slowly. The quickly evolving species then adapts to the slow evolver's needs.

Mutualistic interactions, in which species provide services to one another, are abundant in nature. Examples are everywhere: from the mitochondria, once free-living bacteria that provide energy from burning sugars with oxygen to every cell in our body, to fungi that enable plants to take up nitrogen from the soil, to ants interacting with caterpillars providing them with protection for food. When such an interaction occurs, who will benefit most? Will the ant benefit most by providing very little protection for a lot of food, or will the caterpillar benefit most by providing very little food for a lot of protection?

Michael Lachmann from the Max Planck Institute for Mathematics in the Sciences in Leipzig and Carl Bergstrom from the University of Washington examined this question by using mathematical analysis. One can abstract the behavior of each species as being "generous" and giving much of the benefit to the other species, or being "selfish" and asking for most of the benefit for itself. In a mutualistic interaction, the two species benefit most from coordinating - when one is "generous" and the other "selfish". Benefits to each are less than optimal in other cases - when both are selfish, or both generous.

When the population of one species is all generous, and of the other all selfish, no evolutionary changes can occur, since no species can benefit from changing its behavior. When pairings of selfish-selfish or generous-generous occur in some cases, then evolutionary change might happe
'"/>

Contact: Michael Lachmann
lachmann@mis.mpg.de
49-341-995-9854
Max-Planck-Gesellschaft
17-Jan-2003


Page: 1 2 3

Related biology news :

1. Breast is still best, though breast-fed infants may show initial slower weight gain
2. When plants need ants help, bigger is better
3. Invasive marine animals get bigger
4. Growth hormone could make farm fish bigger, faster to market
5. Museums must play a bigger role in conservation
6. Climate plays bigger role than CO2 in make-up of plant communities
7. Genes play a bigger role in womens depression than in mens, twin study finds
8. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
9. Building the whole cell from pieces
10. The dopamine receptor D1 gene and ADHD: A piece of the genetic puzzle?
11. Researchers find new piece of cell growth puzzle

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evolving slower gets you the bigger piece the pie

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: